Home Journals Articles Updates About
CN
image
收藏切换
Rh(Ⅲ)-catalyzed late-stage C-H alkenylation and macrolactamization for the synthesis of cyclic peptides with unique Trp(C7)-alkene crosslinks
收藏切换
PDF
Shulei Hua, b, Yu Zhangb, c, Xiong Xieb, Luhan Lib, d, Kaixian Chena, b, *, Hong Liua, b, d, *, Jiang Wangb, c, *
Chinese Chemical Letters | 2024, 35(8) : 109408
Less
收藏切换
Chinese Chemical Letters | 2024, 35(8): 109408
• Communication •
Rh(Ⅲ)-catalyzed late-stage C-H alkenylation and macrolactamization for the synthesis of cyclic peptides with unique Trp(C7)-alkene crosslinks
Full
Shulei Hua, b, Yu Zhangb, c, Xiong Xieb, Luhan Lib, d, Kaixian Chena, b, *, Hong Liua, b, d, *, Jiang Wangb, c, *
Affiliations
  • a Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
  • b State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • c Lingang Laboratoty, Shanghai 200031, China
  • d School of Life Science and Technology, ShanghaiTech University, Shanghai 200031, China
Published: 2024-08-15 doi: 10.1016/j.cclet.2023.109408
Outline
收藏切换

Heterocycle-braced cyclic peptides have demonstrated enhanced metabolic stability, increased potency and selectivity. Here, we present a rapid synthesis method for constructing Trp(C7)-alkene(E)-crosslinked cyclic peptides with potent anti-proliferative activities against cancer cells, through C-H alkenylation and macrolactamization. This report addresses critical challenges associated with the installation and removal of the directing group N-Piv, configuration selectivity of the olefin, and intramolecular cyclization. Notably, this method exhibits mild reaction conditions, traceless removal of the directing group, and high configuration selectivity.

C-H functionalization  /  Rh(Ⅲ)-catalyzed  /  Alkenylation  /  Cyclic peptides  /  Macrolactamization
Shulei Hu, Yu Zhang, Xiong Xie, Luhan Li, Kaixian Chen, Hong Liu, Jiang Wang. Rh(Ⅲ)-catalyzed late-stage C-H alkenylation and macrolactamization for the synthesis of cyclic peptides with unique Trp(C7)-alkene crosslinks[J]. Chinese Chemical Letters, 2024 , 35 (8) : 109408 - . DOI: 10.1016/j.cclet.2023.109408
Full Text
Less
Cyclic peptides often display improved metabolic stability, and in many cases, exhibit reduced polar surface area compared to linear peptides [1]. The incorporation of appropriate heterocyclic motifs into the structure of a cyclic peptide has the potential to enhance metabolic stability, increase potency and selectivity [2]. Many natural products possess tryptophan (Trp)-crosslinked macrocycle structures, such as stephanotic acid [3], chloropeptin Ⅱ [4], and celogentin C [5,6], which exhibit various biological activities, including anti-HIV, anti-inflammatory, and anti-fungal [7,8]. The traditional methods for synthesizing the Trp-crosslinked cyclic peptides could be divided into three categories: (a) Utilizing indole and its derivatives as starting materials, (b) transforming tryptophan, and (c) synthesizing the indole fragment via cross-coupling reactions (Fig. 1). However, these methods still have limitations that require further improvement. For example, in the synthesis of stephanotic acid methyl ester from indole derivatives involves racemization, resulting in the generation of cyclic peptides as racemic mixtures (Fig. 1a) [3]. Jia et al. employed protected 6-iodo-L-tryptophan as the indole-containing building block. Unfortunately, it requires five-step to synthesize 6-iodo-L-tryptophan, which leads to a decrease in synthetic efficiency (Fig. 1b) [9]. Larock annulation, an effective method for generating indoles, has been successfully utilized in the construction of Trp-crosslinked cyclic peptides [4,10-12]. However, a series of functional group interconversion steps are required, making these processes cumbersome (Fig. 1c). To overcome these limitations and improve the synthesis of these unique cyclic peptides, further research and innovative approaches are required.
In recent years, the field of C-H functionalization has experienced rapid development [13-20]. Many strategies for site-selective functionalization of indole C-H bonds have been reported (Scheme 1a) [21-30]. However, these chemical strategies are primarily limited to straightforward indole and tryptophan derivatives. The late-stage modification of peptides using C-H functionalization has gained considerable attention due to its high atomic economy, convenient operation, and largely used for the cyclic peptide synthesis [31-34]. Therefore, developing conveniently installed and removal-traceless directing groups with mild reaction conditions for the direct late-stage modification of tryptophan-containing complex peptides are urgently needed. Trp-crosslinked cyclic peptides have been successfully constructed though C2 or C4 C-H activation of tryptophan (Scheme 1b) [32,35-37]. However, the construction of Trp(C7)-crosslinked cyclic peptides is more challenging and only a few successful cases have been reported [11,12]. Recently, Wang and our group have realized the construction of Trp-crosslinked cyclic peptides though C7 C-H activation of tryptophan, respectively [38,39]. The development of these methods opens up exciting opportunities for the efficient and selective modification of complex peptides, and it is expected to have a profound impact on the synthesis of biologically active cyclic peptides with enhanced properties. Further advancements in this field will undoubtedly expand the scope and applicability of C-H functionalization in peptide chemistry.
Heterocycle-alkene-braced cyclic peptides have been discovered in natural products, with some of them exhibiting unique biological activity [40,41]. For instance, cyclotheoneliazole A [41], a natural cyclic peptide, reported to be a potent elastase inhibitor and can alleviate acute lung injury. Given the pivotal role of indole in heterocycles, the development of convenient synthesis methods for Trp-alkene-crosslinked cyclic peptides holds great significance in obtaining novel and biologically active peptide macrocycles. In 2021, Ackermann and co-workers described the use of manganese-catalyzed alkyne hydroarylation raction for obtaining a series of cyclic peptides containing Trp(C2)-alkene crosslinks. This protocol was free of peptide racemization and highly tolerant to a variety of functional groups [42]. Here, we present a novel method for the rapid synthesis of E-configuration Trp(C7)-alkene-crosslinked cyclic peptides with potent anti-proliferative activities against cancer cells from simple linear peptide precursors through the merging of Rh(Ⅲ)-catalyzed pivaloyl (Piv)-directed late-stage C-H alkenylation and macrolactamization. This method overcomes the challenges posed by the large aromatic plane of cyclic peptide products and the unreactive C7 Trp site (Scheme 1c). Our notable findings include: (i) Completely E-configuration Trp(C7)-alkene-crosslinked cyclic peptides could be obtained by C-H alkenylation and the relay of macrolactamization, (ii) three kinds of cyclic peptides could be rapidly obtained by selecting rational designed acrylic esters based on different cyclization reaction sites, and (iii) directing group removal and macrolactamization could be combined into one step.
We initiated our studies by choosing N-Piv-Boc-l-Trp-OMe (1a) and benzyl acrylate (2a) as the template substrates. Initially, a mixture of 1a (0.1 mmol) and 2a (0.3 mmol) was stirred at 80 ℃ in a sealed tube with DCE (1 mL) as the solvent for 12 h under air in the presence of catalyst (10 mol%), AgSbF6 (20 mol%), and Cu(OAc)2 (0.25 mmol) (Table 1, entries 1-4). Through the evaluation of various catalysts, we discovered that the desired product 3aa could be obtained in a 10% yield when [Cp*RhCl2]2 was introduced into the reaction system (Table 1, entry 1). The structure of 3aa was verified via NMR spectra, confirming the E-configuration connection of the alkenyl group to the indole moiety at the C7 position of tryptophan (see Supporting information for details). Subsequently, the influence of Ag salt was explored based on the above results (Table 1, entries 5 and 6). To our delight, AgNTf2 was found to be an essential reagent, elevating the yield of 3aa to 49% upon replacing AgSbF6 with AgNTf2 (Table 1, entry 5). Further study revealed that the yield of 3aa could reach 69% by increasing the equivalent of 2a (4.5 equiv., Table 1, entry 7). Next, the influence of different solvents was examined. Solvent screening indicated that DCE was the best choice for this reaction (Table 1, entries 7-12). Additionally, extending the reaction time to 18 h did not lead to a further increase in yield (Table 1, entry 13). Ultimately, the optimal conditions for synthesizing 3aa were determined as follows: 1a (0.1 mmol), 2a (0.45 mmol), [Cp*RhCl2]2 (10 mol%), AgNTf2 (20 mol%), Cu(OAc)2 (0.25 mmol), in DCE (1 mL) stirred at 110 ℃ under air in a sealed tube for 12 h.
After determining the optimal reaction conditions, we further investigated the scope of this reaction. The coupling of N-Piv-Boc-l-Trp-OMe (1a) with various acrylates were firstly examined. Trp (C7) alkenylation products could be obtained with medium to good yields when simple acrylates participated in this reaction (Scheme 2, 3aa-3ae, 49%-69%). 1a also reacted smoothly with acrylate-modified serine and serine-containing dipeptide (3af, 62%; 3ag, 40%). Different N-Piv installed tryptophan-containing dipeptides were synthesized, and they all reacted well with substrate 2a (3ba-3ka, 31%-75%). Notably, dipeptides containing unprotected asparagine, tryptophan, methionine, and methyl protected serine, as well as benzyl protected glutamic acid residue, successfully coupled with 2a under the optimal conditions (3ga-3ka, 31%-63%). Encouraged by these promising results, we further explored the potential application of this method for the alkenylation of tryptophan-containing tripeptides. Whether the N-Piv installed tryptophan residue was positioned at the N-terminus or C-terminus of the tripeptides, these tripeptides could react with the acrylate-modified serine 2f to obtain tetrapeptides containing the alkene-indole structure (3lf-3pf, 32%-62%).
The ligation of complex peptides randomly composed of tryptophan, leucine, phenylalanine, glycine, alanine, β-alanine, isoleucine, proline, protected glutamate, and protected aspartate with acrylates were further explored. To our delight, the determined optimal conditions remained effective for these Trp-containing tetrapeptides to hexapeptides (Scheme 3, 3qh-3th, 3ta, 3ui-3vi, 3wj-3yj, 39%-53%). The late-stage C-H alkenylation of these complex peptides served as a robust foundation, enabling the subsequent synthesis of a diverse array of cyclic peptides.
Furthermore, a gram scale synthesis of 3ah was carried out with 64% isolated yield, further confirmed the practicality of this method (Scheme 4a). The conditions for deprotection and directing groups removal were examined. The directing group pivaloyl (Piv) of 3ah could be easily removed in the presence of triethylamine, and the addition of water being crucial for facilitating a smooth reaction, leading to the formation of the corresponding product 4ah in a yield of 99% (Scheme 4b). The protecting groups t-butyloxy carbonyl (Boc) and t-butyl (tBu) of 3ah were effectively removed under acidic conditions without affecting the directing group, affording 4ah-2 in a yield of 99% (Scheme 4c). Moreover, the methyl ester group of 3ah could be selectively hydrolyzed with Me3SnOH [43] as the base without affecting N-Piv, Boc, tBu, and most importantly, the acrylic ester moiety (Scheme 4d). The acid 4ah-3 could be obtained in a yield of 83%. The formation of the carboxylic acid group in 4ah-3 provides a suitable reaction site for further modification, enabling the synthesis of more complex and diverse cyclic peptides.
To obtain the Trp(C7)-alkene(E)-crosslinked cyclic peptides, we utilized a C-H alkenylation & macrolactamization strategy (Fig. 2). Starting from a linear peptide substrate, three different peptide macrocycles could be quickly obtained by selecting rational designed acrylic esters as alkenyl substrates and selecting different cyclization reaction sites, including the native C-terminus, N-terminus, and the glutamate/aspartate side chain. As shown in Fig. 2, a tert-butyl ester-containing fragment is introduced at the C7 position of tryptophan residue of linear peptide substrate by C-H alkenylation. After selective deprotection, the newly formed carboxylic acid undergoes macrolactamization with the N-terminal amino group to generate head-to-side chain cyclic peptide. Similarly, the side chain-to-tail cyclic peptide could be achieved using the allyl ester, which containing a Boc protected amino segment, in the C-H alkenylation step and relaying through macrolactamization. In addition, this strategy could also link the tryptophan side chain with the glutamate or aspartate side chain to obtain side chain-to-side chain cyclic peptide. It is worth noting that the directing group N-Piv could be removed during the condensation process using finely tuned conditions, resulting in products closely resemble natural cyclic peptides.
We explored the possibility of constructing challenging Trp(C7)-alkene(E)-crosslinked cyclic peptides, focusing on 3qh, 3rh, 3th, 3ui, 3vi, 3xj and 3yj for cyclization investigation. Firstly, the protecting groups Boc and tBu were removed from 3yj under acidic conditions. The resulting intermediate was then stirred at room temperature for 18 h using 3-(diethoxyphosphoryloxy)-1, 2, 3-benzotrizin-4(3H)-one (DEPBT) [44-46] as the condensation agent, which has been confirmed to be an efficient condensation agent and has been successfully used in the total syntheses of various complex cyclic peptides. Subsequently, the side chain-to-tail 30-membered cyclic peptide 5yj was isolated in 33% yield (Scheme 5a). Moreover, the side chain-to-side chain 25-membered cyclic peptide 5xj could be obtained in 32% yield from the linear peptide 3xj (Scheme 5b). Finally, a series of head-to-side chain cyclic peptides with different structures and sizes (5qh, 5rh, 5th, 5ui, 5vi, 25-30 membered macrocycles, 28%-35% yield) were successfully synthesized using this strategy (Scheme 5c). These results demonstrate the effectiveness of our method in constructing challenging Trp(C7)-alkene(E)-crosslinked cyclic peptides with different ring sizes and topologies, providing a practical and efficient tool for the creation of structurally diverse cyclic peptides with potential applications in drug discovery and other biotechnological fields.
Next, we determined the effects of the selected linear peptides and cyclic peptides on the proliferation of HCC1806 cells (human breast cancer cells). Cyclic peptides 5rh and 5vi exhibited significant anti-proliferative activity with 97% and 99% inhibition rate at 30 µmol/L, respectively (Fig. 3). The IC50 value of 5vi was further determined to be 15.44 µmol/L (see Supporting Information for details). These results indicated that compounds 5vi and 5rh exhibit potent anti-proliferative activity against cancer cells.
In summary, we have provided an efficient method for the construction of cyclic peptides with unique Trp(C7)-alkene(E)-crosslinks, starting from easily accessible linear peptide precursors, through the merging of Rh(Ⅲ)-catalyzed Piv-directed late-stage C-H alkenylation and macrolactamization. This method exhibits mild reaction conditions, traceless removal of the directing group, and high configuration selectivity. Three kinds of cyclic peptides could be quickly obtained by selecting rational designed acrylic esters based on different cyclization reaction sites. 25- to 30-membered cyclic peptides were successfully constructed using this method, and cyclic peptides 5rh and 5vi exhibited potent anti-proliferative activity against cancer cells. Our findings laid a solid foundation for subsequent research of these compounds in the field of medicinal chemistry and pharmacology. Moreover, this method also has significant reference value for synthesizing cyclic peptides with other C7-modified Trp crosslinks.
Declaration of competing interest
Less
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgments
Less
We gratefully acknowledge the National Key R&D Program of China (No. 2022YFA1302900 to H. Liu), National Natural Science Foundation of China (Nos. 82130105, 22337003 and 82121005 to H. Liu; and Nos. 22177124, 82322063 to J. Wang), Program of Shanghai Academic Research Leader (No. 23XD1460300 to J. Wang), the Lingang Laboratory (No. LG-GG-202204-02 to J. Wang) for supporting this work. We would like to acknowledge Shanghai Highline Therapeutics. Inc for their assistance in the biological activity assay.
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2023.109408.
References
Less
[1]
D.S. Nielsen, N.E. Shepherd, W. Xu, A.J. Lucke, M.J. Stoermer, Chem. Rev. 117 (2017) 8094–8128.
[2]
I.V. Smolyar, A.K. Yudin, V.G. Nenajdenko, Chem. Rev. 119 (2019) 10032–10240.
[3]
D.J. Bentley, A.M.Z. Slawin, C.J. Moody, Org. Lett. 8 (2006) 1975–1978.
[4]
J. Garfunkle, F.S. Kimball, J.D. Trzupek, et al., J. Am. Chem. Soc. 131 (2009) 16036–16038.
[5]
J. Kobayashi, H. Suzuki, K. Shimbo, K. Takeya, H. Morita, J. Org. Chem. 66 (2001) 6626–6633.
[6]
D. Feng, L. Liu, Y. Shi, et al., Chin. Chem. Lett. 34 (2023) 108026.
[7]
H. Tanaka, K. Matsuzaki, H. Nakashima, et al., J. Antibiot. 50 (1997) 58–65.
[8]
E. Hamel, Med. Res. Rev. 16 (1996) 207–231.
[9]
L. Li, W. Hu, Y. Jia, Tetrahedron 70 (2014) 7753–7762.
[10]
H. Shimamura, S.P. Breazzano, J. Garfunkle, et al., J. Am. Chem. Soc. 132 (2010) 7776–7783.
[11]
N.A. Isley, Y. Endo, Z. Wu, et al., J. Am. Chem. Soc. 141 (2019) 17361–17369.
[12]
M. Nesic, D.B. Ryffel, J. Maturano, et al., J. Am. Chem. Soc. 144 (2022) 14026–14030.
[13]
Z. Dong, Z. Ren, S.J. Thompson, Y. Xu, G. Dong, Chem. Rev. 117 (2017) 9333–9403.
[14]
R. Zhu, M.E. Farmer, Y. Chen, J. Yu, Angew. Chem. Int. Ed. 55 (2016) 10578–10599.
[15]
B. Liu, A.M. Romine, C.Z. Rubel, K.M. Engle, B. Shi, Chem. Rev. 121 (2021) 14957–15074.
[16]
R. Zhang, S. Luo, Chin. Chem. Lett. 29 (2018) 1193–1200.
[17]
X. Han, P. Lin, Q. Li, Chin. Chem. Lett. 30 (2019) 1495–1502.
[18]
H. Xu, Y. Zhu, X. Chai, J. Yang, L. Dong, Green Synth. Catal. 1 (2020) 167–170.
[19]
J. Zhang, L. Yao, J. Su, et al., Green Synth. Catal. 4 (2023) 206–225.
[20]
W. Shang, H. Sun, W. Chen, J. Liu, Green Synth. Catal. 4 (2023) 104–123.
[21]
I. Choi, A.M. Messsinis, L. Ackermann, Angew. Chem. Int. Ed. 59 (2020) 12534–12540.
[22]
S. Fang, G. Jiang, M. Li, et al., Chem. Comm. 55 (2019) 13769.
[23]
X. Shi, Z. Wang, Y. Li, et al., Angew. Chem. Int. Ed. 60 (2021) 13871–13876.
[24]
D. Wang, X. Chen, J.J. Wong, et al., Nat. Commun. 12 (2021) 524.
[25]
Y. Sheng, Y. Gao, B. Duan, et al., Adv. Synth. Catal. 364 (2022) 307–313.
[26]
X. Qiu, H. Deng, Y. Zhao, Z. Shi, Sci. Adv. 4 (2018) eaau6468.
[27]
Y. Sheng, J. Zhou, Y. Gao, et al., J. Org. Chem. 86 (2021) 2827–2839.
[28]
C.N. Kona, Y. Nishii, M. Miura, Org. Lett. 23 (2021) 6252–6256.
[29]
Y. Yang, R. Li, Y. Zhao, D. Zhao, Z. Shi, J. Am. Chem. Soc. 138 (2016) 8734–8737.
[30]
J. Lv, X. Chen, X. Xue, et al., Nature 575 (2019) 336–340.
[31]
B. Li, X. Li, B. Han, et al., J. Am. Chem. Soc. 141 (2019) 9401–9407.
[32]
Z. Bai, C. Cai, W. Sheng, Y. Ren, H. Wang, Angew. Chem. Int. Ed. 59 (2020) 14686–14692.
[33]
J. Tang, Y. He, H. Chen, W. Sheng, H. Wang, Chem. Sci. 8 (2017) 4565–4570.
[34]
M.M. Lorion, N. Kaplaneris, J. Son, R. Kuniyil, L. Ackermann, Angew. Chem. Int. Ed. 58 (2019) 1684–1688.
[35]
J. Peng, C. Li, M. Khamrakulv, J. Wang, H. Liu, Org. Lett. 22 (2020) 1535–1541.
[36]
J. Li, J. Sun, X. Zhang, et al., Chem. Commun. 59 (2023) 868–871.
[37]
Z. Ruan, N. Sauermann, E. Manoni, L. Ackermann, Angew. Chem. Int. Ed. 56 (2017) 3172–3176.
[38]
L. Liu, X. Fan, B. Wang, et al., Angew. Chem. Int. Ed. 61 (2022) e202206177.
[39]
Y. Zhang, S. Hu, Y. Li, et al., Org. Lett. 25 (2023) 2456–2460.
[40]
M.T. Jamison, T.F. Molinski, J. Nat. Prod. 79 (2016) 2243–2249.
[41]
Y. Cui, M. Zhang, H. Xu, et al., J. Med. Chem. 65 (2022) 2971–2987.
[42]
N. Kaplaneris, F. Kaltenhausar, G. Sirvinskaite, et al., Sci. Adv. 7 (2021) eabe6202.
[43]
K.C. Nicolaou, A.A. Estrada, M. Zak, S.H. Lee, B.S. Safina, Angew. Chem. Int. Ed. 44 (2005) 1378–1382.
[44]
C. Fan, X. Hao, Y. Ye, Synth. Commun. 26 (1996) 1455–1460.
[45]
A. Okano, N.A. Isley, D.L. Boger, Chem. Rev. 117 (2017) 11952–11993.
[46]
A. Guzman-Martinez, R. Lamer, M.S. Van Nieuwenhze, J. Am. Chem. Soc. 129 (2007) 6017–6021.
Appendix
Less
Year 2024 volume 35 Issue 8
PDF
49
27
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2023.109408
  • Receive Date：2023-10-18
  • Online Date：2025-11-21
  • Published：2024-08-15
Article Data
Affiliations
History
  • Received：2023-10-18
  • Revised：2023-12-05
  • Accepted：2023-12-14
Affiliations
    a Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
    b State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
    c Lingang Laboratoty, Shanghai 200031, China
    d School of Life Science and Technology, ShanghaiTech University, Shanghai 200031, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2023.109408
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House